| |
| Device | Edwards EVOQUE Tricuspid Valve Replacement System |
| Generic Name | Percutaneously Delivered Prostheses and Tricuspid Valves |
| Applicant | Edwards Lifesciences, LLC One Edwards Way Irvine, CA 92614 |
| PMA Number | P230013 |
| Date Received | 03/31/2023 |
| Decision Date | 02/01/2024 |
| Product Code |
NPW |
| Docket Number | 24M-0303 |
| Notice Date | 02/02/2024 |
| Advisory Committee |
Cardiovascular |
| Clinical Trials | NCT04482062
|
| Expedited Review Granted? | No |
| Combination Product | No |
| Predetermined Change Control Plan Authorized | No |
| Recalls | CDRH Recalls |
Approval Order Statement Approval for the Edwards EVOQUE Tricuspid Valve Replacement System. The device is indicated for the improvement of health status in patients with symptomatic severe tricuspid regurgitation (TR) despite optimal medical therapy (OMT), in whom tricuspid valve replacement is deemed appropriate by a heart team. |
| Approval Order | Approval Order |
| Summary | Summary of Safety and Effectiveness |
| Labeling | Labeling Labeling Part 2 |
| Post-Approval Study | Show Report Schedule and Study Progress |
| Supplements: |
S013 S014 S015 S018 S019 S020 S021 S026 S027 S028 S029 S030 S006 S007 S008 S016 S017 S010 S001 S002 S003 S004 S005 S012 S009 S022 S023 S031 S032 S033 S034 S024 S025 |